Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 8
2013 2
2014 4
2015 5
2016 2
2017 6
2018 5
2019 4
2020 7
2021 6
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study.
Casula M, Gazzotti M, Capra ME, Olmastroni E, Galimberti F, Catapano AL, Pederiva C; LIPIGEN Group and the LIPIGEN Paediatric Group. Casula M, et al. Atherosclerosis. 2023 Nov;385:117231. doi: 10.1016/j.atherosclerosis.2023.117231. Epub 2023 Aug 12. Atherosclerosis. 2023. PMID: 37648636 Free article.
Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units.
Scicali R, Mandraffino G, Scuruchi M, Lo Gullo A, Di Pino A, Ferrara V, Morace C, Aragona CO, Squadrito G, Purrello F, Piro S. Scicali R, et al. Among authors: scuruchi m. Biomedicines. 2022 Jul 15;10(7):1715. doi: 10.3390/biomedicines10071715. Biomedicines. 2022. PMID: 35885020 Free PMC article.
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy.
Toscano A, Cinquegrani M, Scuruchi M, Di Pino A, Piro S, Ferrara V, Morace C, Lo Gullo A, Imbalzano E, Purrello F, Squadrito G, Scicali R, Mandraffino G. Toscano A, et al. Among authors: scuruchi m. Biomolecules. 2022 Apr 9;12(4):562. doi: 10.3390/biom12040562. Biomolecules. 2022. PMID: 35454151 Free PMC article.
Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: Real-world data from two lipid units.
Scicali R, Mandraffino G, Di Pino A, Scuruchi M, Ferrara V, Squadrito G, Purrello F, Piro S. Scicali R, et al. Among authors: scuruchi m. Nutr Metab Cardiovasc Dis. 2021 Nov 29;31(12):3401-3406. doi: 10.1016/j.numecd.2021.08.034. Epub 2021 Aug 19. Nutr Metab Cardiovasc Dis. 2021. PMID: 34627693
50 results